Does Dolutegravir Sodium And Rilpivirine Hydrochloride Interact with Dalfampridine?
CDI records a contraindicated classification for Dolutegravir Sodium And Rilpivirine Hydrochloride and Dalfampridine. The stored summary is: Dolutegravir inhibits OCT2 and MATE1, increasing dalfampridine plasma concentrations. Consider alternatives due to risk of Torsade de Pointes. The mechanism involves inhibition of renal organic cation transporter 2 (oct2) and multidrug and toxin extrusion transporter 1 (mate1). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Dalfampridine Class
- Potassium Channel Blocker
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1)
What To Tell Your Doctor or Pharmacist
If you are taking Dolutegravir Sodium And Rilpivirine Hydrochloride and your doctor is considering prescribing Dalfampridine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider